Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxiety

Molecular Psychiatry

Volumn 18, Issue 3, 2013, Pages 308-319

  Sink, K S ^a   Walker, D L ^a   Freeman, S M ^a   Flandreau, E I ^a   Ressler, K J ^a   Davis, M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anxiety; bed nucleus of the stria terminalis; corticotropin releasing factor; fear; HPA axis; startle

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BED NUCLEUS OF THE STRIA TERMINALIS; BRAIN NUCLEUS; CONDITIONING; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DORSAL RAPHE NUCLEUS; FEAR; GENE OVEREXPRESSION; MALE; MAZE TEST; MEMORY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; STRIA TERMINALIS;

ANIMALS; ANXIETY; CONDITIONING (PSYCHOLOGY); CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; MALE; NEURONS; RAPHE NUCLEI; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEPTAL NUCLEI;

EID: 84884211377     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.188     Document Type: Article

References (91)

1. Davis M, Walker DL, Miles L, Grillon C. Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 2010; 35: 105-135.
2. Walker DL, Davis M. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci 1997; 17: 9375-9383.
3. Sullivan GM, Apergis J, Bush DE, Johnson LR, Hou M, Ledoux JE. Lesions in the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear stimulus. Neuroscience 2004; 128: 7-14.
4. Waddell J, Morris RW, Bouton ME. Effects of bed nucleus of the stria terminalis lesions on conditioned anxiety: aversive conditioning with long-duration conditional stimuli and reinstatement of extinguished fear. Behav Neurosci 2006; 120: 324-336.
5. Sink KS, Walker DL, Yang Y, Davis M. Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures. J Neurosci 2011; 31: 1802-1810.
6. Fox AS, Shelton SE, Oakes TR, Converse AK, Davidson RJ, Kalin NH. Orbitofrontal cortex lesions alter anxiety-related activity in the primate bed nucleus of stria terminalis. J Neurosci 2010; 30: 7023-7027.
7. Kalin NH, Shelton SE, Fox AS, Oakes TR, Davidson RJ. Brain regions associated with the expression and contextual regulation of anxiety in primates. Biol Psychiatry 2005; 58: 796-804.
8. Somerville LH, Whalen PJ, Kelley WM. Human bed nucleus of the stria terminalis indexes hypervigilant threat monitoring. Biol Psychiatry 2010; 68: 416-424.
9. Straube T, Mentzel HJ, Miltner WH. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. Neuroimage 2007; 37: 1427-1436.
10. Gray TS, Magnuson DJ. Neuropeptide neuronal efferents from the bed nucleus of the stria terminalis and central amygdaloid nucleus to the dorsal vagal complex in the rat. J Comp Neurol 1987; 262: 365-374.
11. Merchenthaler I, Vigh S, Petrusz P, Schally AV. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat 1982; 165: 385-396.
12. Phelix CF, Paull WK. Demonstration of distinct corticotropin releasing factor-containing neuron populations in the bed nucleus of the stria terminalis. A light and electron microscopic immunocytochemical study in the rat. Histochemistry 1990; 94: 345-364.
13. Dunn AJ, Berridge CW. Is corticotropin-releasing factor a mediator of stress responses? Ann NY Acad Sci ,1990, 579: 183-191.
14. Keen-Rhinehart E, Michopoulos V, Toufexis DJ, Martin EI, Nair H, Ressler KJ et al. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry 2009; 14: 37-50.
15. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43: 425-473.
16. Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann NYAcad Sci 1993; 697: 173-188.
17. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(Suppl 7): 5-13.
18. Hubbard DT, Nakashima BR, Lee I, Takahashi LK. Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear. Neuroscience 2007; 150: 818-828.
19. Pitts MW, Takahashi LK. The central amygdala nucleus via corticotropin-releasing factor is necessary for time-limited consolidation processing but not storage of contextual fear memory. Neurobiol Learn Mem 2011; 95: 86-91.
20. Risbrough VB, Geyer MA, Hauger RL, Coste S, Stenzel-Poore M, Wurst W et al. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 2009; 34: 1494-1503.
21. Skorzewska A, Bidzinski A, Hamed A, Lehner M, Turzynska D, Sobolewska A et al. The effect of CRF and alpha-helical CRF((9-41)) on rat fear responses and amino acids release in the central nucleus of the amygdala. Neuropharmacology 2009; 57: 148-156.
22. Walker DL, Miles LA, Davis M. Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1291-1308.
23. Regev L, Neufeld-Cohen A, Tsoory M, Kuperman Y, Getselter D, Gil S et al. Prolonged and site-specific over-expression of corticotropinreleasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry 2011; 16: 714-728.
24. Vicentini E, Arban R, Angelici O, Maraia G, Perico M, Mugnaini M et al. Transient forebrain over-expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice. Pharmacol Biochem Behav 2009; 93: 17-24.
25. Bale TL. Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm Behav 2005; 48: 1-10.
26. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 2004; 311: 427-440.
27. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24: 580-588.
28. Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 2006; 50: 550-561.
29. Zorrilla EP, Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004; 13: 799-828.
30. Rodrigues SM, LeDoux JE, Sapolsky RM. The influence of stress hormones on fear circuitry. Annu Rev Neurosci 2009; 32: 289-313.
31. Choi DC, Nguyen MM, Tamashiro KL, Ma LY, Sakai RR, Herman JP. Chronic social stress in the visible burrow system modulates stress-related gene expression in the bed nucleus of the stria terminalis. Physiol Behav 2006; 89: 301-310.
32. Funk D, Li Z, Le AD. Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: Relationship to the reinstatement of alcohol seeking. Neuroscience 2006; 138: 235-243.
33. Kim SJ, Park SH, Choi SH, Moon BH, Lee KJ, Kang SWet al. Effects of repeated tianeptine treatment on CRF mRNA expression in nonstressed and chronic mild stress-exposed rats. Neuropharmacology 2006; 50: 824-833.
34. Shepard JD, Schulkin J, Myers DA. Chronically elevated corticosterone in the amygdala increases corticotropin releasing factor mRNA in the dorsolateral bed nucleus of stria terminalis following duress. Behav Brain Res 2006; 174: 193-196.
35. Gray TS, Magnuson DJ. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992; 13: 451-460.
36. Moga MM, Saper CB, Gray TS. Bed nucleus of the stria terminalis: cytoarchitecture, immunohistochemistry, and projection to the parabrachial nucleus in the rat. J Comp Neurol 1989; 283: 315-332.
37. Panguluri S, Saggu S, Lundy R. Comparison of somatostatin and corticotrophin-releasing hormone immunoreactivity in forebrain neurons projecting to taste-responsive and non-responsive regions of the parabrachial nucleus in rat. Brain Res 2009; 1298: 57-69.
38. Champagne D, Beaulieu J, Drolet G. CRFergic innervation of the paraventricular nucleus of the rat hypothalamus: a tract-tracing study. J Neuroendocrinol 1998; 10: 119-131.
39. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
40. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
41. Flandreau EI, Ressler KJ, Owens MJ, Nemeroff CB. Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus. Psychoneuroendocrinology 2012; 37: 27-38.
42. Seth KA, Majzoub JA. Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. J Biol Chem 2001; 276: 13917-13923.
43. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100: 1844-1848.
44. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampusspecific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 2007; 12: 656-670.
45. Rattiner LM, Davis M, French CT, Ressler KJ. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. J Neurosci 2004; 24: 4796-4806.
46. Keene O. The log transformation is special. Stat Med 1995; 14: 811-819.
47. Miles L, Davis M, Walker D. Phasic and sustained fear are pharmacologically dissociable in rats. Neuropsychopharmacology 2011; 36: 1563-1574.
48. Gutman DA, Owens MJ, Thrivikraman KV, Nemeroff CB. Persistent anxiolytic affects after chronic administration of the CRF receptor antagonist R121919 in rats. Neuropharmacology 2011; 60: 1135-1141.
49. Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 1992; 581: 190-197.
50. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994; 49: 171-176.
51. Ressler KJ, Paschall G, Zhou XL, Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci 2002; 22: 7892-7902.
52. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 3rd edn. Academic Press: San Diego, 1997.
53. Ahern TH, Young LJ. The impact of early life family structure on adult social attachment, alloparental behavior, and the neuropeptide systems regulating affiliative behaviors in the monogamous prairie vole (Microtus ochrogaster). Front Behav Neurosci 2009; 3: 17.
54. Lim MM, Nair HP, Young LJ. Species and sex differences in brain distribution of corticotropin-releasing factor receptor subtypes 1 and 2 in monogamous and promiscuous vole species. J Comp Neurol 2005; 487: 75-92.
55. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995; 15: 6340-6350.
56. Souza MS, de Souza DW, Carvalho Odos S, Neves J, Massara CL. [Viability of Ascaris lumbricoides ova after human treatment with specific drugs. I-Levamisole and pyrantel pamoate]. Rev Inst Med Trop Sao Paulo 1985; 27: 197-200.
57. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000; 428: 191-212.
58. Phelps SM, Young LJ. Extraordinary diversity in vasopressin (V1a) receptor distributions among wild prairie voles (Microtus ochrogaster): patterns of variation and covariation. J Comp Neurol 2003; 466: 564-576.
59. Martin EI, Ressler KJ, Jasnow AM, Dabrowska J, Hazra R, Rainnie DG et al. A novel transgenic mouse for gene-targeting within cells that express corticotropin-releasing factor. Biol Psychiatry 2010; 67: 1212-1216.
60. Gresack JE, Scott CN, Niemeyer CM, Steen HA, Vicentini E, Mangiarini L et al. Transient forebrain CRF overexpression in adulthood selectively impairs contextual fear memory and context habituation. 40th Annual Society for Neuroscience Meeting 2010.
61. Laryea G, Muglia L. Tetracycline-regulated corticotropin-releasing hormone expression in transgenic mice as a model for isolating brain-region specific function in the stress response. 40th Annual Society for Neuroscience Meeting 2010.
62. Cole BJ, Koob GF. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J Pharmacol Exp Ther 1988; 247: 902-910.
63. Radulovic J, Ruhmann A, Liepold T, Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 1999; 19: 5016-5025.
64. Sherman JE, Kalin NH. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol Biochem Behav 1988; 30: 801-807.
65. Cahill L, Gorski L, Le K. Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learn Mem 2003; 10: 270-274.
66. Hui IR, Hui GK, Roozendaal B, McGaugh JL, Weinberger NM. Posttraining handling facilitates memory for auditory-cue fear conditioning in rats. Neurobiol Learn Mem 2006; 86: 160-163.
67. Rau V, DeCola JP, Fanselow MS. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev 2005; 29: 1207-1223.
68. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994; 14(5 Part 1): 2579-2584.
69. Lee Y, Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci 1997; 17: 6434-6446.
70. Lee Y, Davis M. Role of the septum in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci 1997; 17: 6424-6433.
71. Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 1992; 12: 2303-2312.
72. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 1991; 103: 227-232.
73. Koob GF, Bloom FE. Corticotropin-releasing factor and behavior. Fed Proc 1985; 44(1 Part 2): 259-263.
74. Choi DC, Furay AR, Evanson NK, Ostrander MM, Ulrich-Lai YM, Herman JP. Bed nucleus of the stria terminalis subregions differentially regulate hypothalamic-pituitary-adrenal axis activity: implications for the integration of limbic inputs. J Neurosci 2007; 27: 2025-2034.
75. Gray TS, Piechowski RA, Yracheta JM, Rittenhouse PA, Bethea CL, Van de Kar LD. Ibotenic acid lesions in the bed nucleus of the stria terminalis attenuate conditioned stress-induced increases in prolactin, ACTH and corticosterone. Neuroendocrinology 1993; 57: 517-524.
76. Gagliano H, Fuentes S, Nadal R, Armario A. Previous exposure to immobilisation and repeated exposure to a novel environment demonstrate a marked dissociation between behavioral and pituitary-adrenal responses. Behav Brain Res 2008; 187: 239-245.
77. Kalin NH, Takahashi LK. Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res 1990; 509: 80-84.
78. Lee Y, Schulkin J, Davis M. Effect of corticosterone on the enhancement of the acoustic startle reflex by corticotropin releasing factor (CRF). Brain Res 1994; 666: 93-98.
79. Markovic D, Punn A, Lehnert H, Grammatopoulos DK. Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 2008; 22: 689-706.
80. Milan-Lobo L, Gsandtner I, Gaubitzer E, Runzler D, Buchmayer F, Kohler G et al. Subtype-specific differences in corticotropinreleasing factor receptor complexes detected by fluorescence spectroscopy. Mol Pharmacol 2009; 76: 1196-1210.
81. Oakley RH, Olivares-Reyes JA, Hudson CC, Flores-Vega F, Dautzenberg FM, Hauger RL. Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol Regul Integr Comp Physiol 2007; 293: R209-R222.
82. Perry SJ, Junger S, Kohout TA, Hoare SR, Struthers RS, Grigoriadis DE et al. Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. J Biol Chem 2005; 280: 11560-11568.
83. Adamec R, Fougere D, Risbrough V. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD. Int J Neuropsychopharmacol 2010; 13: 747-757.
84. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 2004; 24: 6545-6552.
85. Hammack SE, Pepin JL, DesMarteau JS, Watkins LR, Maier SF. Low doses of corticotropin-releasing hormone injected into the dorsal raphe nucleus block the behavioral consequences of uncontrollable stress. Behav Brain Res 2003; 147: 55-64.
86. Hammack SE, Richey KJ, Schmid MJ, LoPresti ML, Watkins LR, Maier SF. The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J Neurosci 2002; 22: 1020-1026.
87. Mo B, Feng N, Renner K, Forster G. Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors. Brain Res Bull 2008; 76: 493-498.
88. Price ML, Kirby LG, Valentino RJ, Lucki I. Evidence for corticotropin-releasing factor regulation of serotonin in the lateral septum during acute swim stress: adaptation produced by repeated swimming. Psychopharmacology (Berl) 2002; 162: 406-414.
89. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003; 463: 235-272.
90. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
91. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH et al. Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience 2006; 141: 1047-1055.